Breakthrough-Therapy Designation — An FDA Perspective
Breakthrough-Therapy Designation — An FDA Perspective
About this item
Full title
Breakthrough-Therapy Designation — An FDA Perspective
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2018-04, Vol.378 (15), p.1457-1458
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
More information
Scope and Contents
Contents
The authors provide a perspective on the rationale and goals of the designation of “breakthrough therapy” by the Food and Drug Administration.
Alternative Titles
Full title
Breakthrough-Therapy Designation — An FDA Perspective
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2024467511
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2024467511
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1801222
